Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
Date:2/20/2008

llion (US$2.5 million).

-- Earnings per American depositary share ("ADS") for the fourth quarter

2007 were RMB0.82 (US$0.11), compared to RMB0.50 for the fourth quarter

2006.

Fiscal Year 2007 Financial Highlights:

Compared to fiscal year 2006 results,

-- Total net revenues increased 41.0% to RMB180.2 million (US$24.7

million).

-- Net revenue from EPIAO increased 22.6% to RMB121.2 million (US$16.6

million).

-- Net revenue from TPIAO increased 168.3% to RMB43.1 million (US$5.9

million).

-- Revenue from export sales increased 15.4% to RMB6.8 million (US$0.9

million).

-- Operating income increased 32.9% to RMB48.5 million (US$6.7 million).

-- Net income increased 167.4% to RMB81.5 million (US$11.2 million).

-- Earnings per ADS were RMB3.89 (US$0.53) in 2007, compared to RMB2.13

per ADS in 2006.

Commenting on the results, Dr. Jing Lou, Chief Executive Officer of 3SBio, said, ''2007 was a transformative year for 3SBio, driven by the successful and consistent execution of our strategy. We experienced solid growth across our core product portfolio, and delivered on a number of operational initiatives including continued progress on our development pipeline, the introduction of an oncology-focused sales team, the launch of a new product, and the successful groundbreaking on our new manufacturing facility, among others. From a product perspective, we believe our EPIAO products continued to be the market leader in terms of both revenues and sales volume. Our TPIAO products continued their strong growth, accounting for 23.9% of our total net revenues for the year, up from 12.6% for the fiscal year 2006, demonstrating the robust and rapid market acceptance of this product.''

''Our positive results for the fourth quarter and the full year 2007 are consistent with the financial and operational track record that we have achieved since our incepti
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. 3SBio Inc. Announces Change to the Board of Directors
2. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
3. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
5. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
6. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
9. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... studies for its newly developed Bruton,s tyrosine kinase ... been completed. The results of these preclinical evaluations ... Drug Administration. The feedback received from the Agency ... first-in-human study. Additional preclinical work is required to ...
(Date:2/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has ... Trypsin" report to their offering. , ... comprehensive data on Trypsin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:2/27/2015)... 27, 2015 The fully automated ... UC) can sequentially analyze up to 48 samples ... high-sensitivity detection of targets by mass spectrometry. ... fulfill the measurement requirements of a wide range ... drug delivery and search for disease biomarkers, additives ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... Scientific Corporation (NYSE: BSX ) has ... with left main coronary disease who were treated ... SYNTAX-LE MANS is a substudy of the landmark ...
... ( http://www.gene2drug.com ) -- the ... science industry -- announces the publication of its latest ... for Commercial Suppliers, Vol. III." Given the highly ... report is designed to create opportunities for differentiation by ...
... Cholesterol Test for determining heart disease riskBIRMINGHAM, Ala., May ... developer of the VAP Cholesterol Test, has announced it ... and report apolipoprotein B100 (apoB) using the Vertical Auto ... of the VAP Cholesterol Test to accurately report apoB, ...
Cached Biology Technology:SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5BioInformatics, LLC New Report -- The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III 2Atherotech Receives Patent for ApoB Measurement 2Atherotech Receives Patent for ApoB Measurement 3
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... PITTSBURGH, Oct. 23 A new study suggests that viruses ... cells while promoting the growth of surviving cells with cancerous ... wiping out normal cells that support the replication of viruses ... their circuitry. When this process is repeated over and over, ...
... David Jones, a fisheries oceanographer at the Cooperative Institute for ... Miamis Rosenstiel School, set out to design a better light ... invention would contribute to the discovery of a new species. ... known description, his catch turned out to be the answer ...
... Captains Log originally used with individuals diagnosed ... learning disabilities is being adapted to rehabilitate ... Michael Boivin, a Michigan State University associate ... and Bruno Giordani, a University of Michigan associate ...
Cached Biology News:Study proposes new theory of how viruses may contribute to cancer 2New light trap captures larval stage of new species; DNA barcode technology used 2MSU researcher helps develop computer game for Ugandan children recovering from cerebral malaria 2
...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... is a protein ribonuclease inhibitor that noncovalently binds ... inhibition is seen with RNase 1, T1, T2, ... from human placental ribonuclease inhibitor in that it ... does not release active RNase in the absence ...
... Inkjet Printer) is a revolutionary new ... Protein Macroarray Analysis, developed in conjunction ... strategy compliments established protocols in resolving ... proteins isoelectric point and apparent molecular ...
Biology Products: